Classical Hodgkin lymphoma (cHL) is a distinct malignancy of the immune system. Despite the progress made in the understanding of the biology of cHL, the transforming events remain to be elucidated. Recently, we demonstrated that the Janus kinase inhibitor AG490 blocked cellular proliferation and STAT3 phosphorylation in cHL. To explore the potential of constitutively activated STAT3 as a drug target and its role in cHL pathogenesis, different cHL cell lines were analyzed. Treatment of cHL cells by the protein tyrosine kinase inhibitor AG17 was associated with inhibition of cellular proliferation and cell cycle arrest. AG17 treatment was accompanied by decreased levels of STAT3 phosphorylation, whereas NF-jB and p38/SAPK2 signaling were not inhibited. Incubation with AG17 or AG490 sensitized cHL cells to CD95/Fas/Apo-1 or staurosporinemediated apoptosis. Coincubation of tyrphostins with staurosporine was accompanied by rapid complete inhibition of STAT3 phosphorylation. RNA interference directed against STAT3 in L428 and L1236 cHL cells demonstrated that STAT3 is essential for cell proliferation of these cHL cells. In conclusion, these findings support the concept that STAT3 signaling is important in the pathogenesis of cHL and tyrphostins are agents for developing new therapeutic strategies. Leukemia (2005) 19, 936-944.
Introduction
Classical Hodgkin lymphoma (cHL) is a malignancy of unknown pathogenesis. The hallmark of cHL is the presence of large, mononucleated Hodgkin and multinucleated Reed/Sternberg (HRS) cells. 1 Due to the low abundance of malignant cells, it has been difficult to define the transforming event leading to the development of cHL. Several HRS cell lines have been established, which can serve as suitable model systems to define factors important to maintain the transformed phenotype of this lymphoma. [2] [3] [4] We and others showed that STAT3 is constitutively activated in cHL cell lines and in primary HRS cells, demonstrating that deregulated STAT3 may play a causative role in this tumor. [5] [6] [7] However, in contrast to other malignancies, it is still unknown to what extent constitutively activated STAT3 is involved in transformation of cHL cells. Inhibition of constitutively activated STAT3 using the Janus kinase (Jak) inhibitor AG490 was accompanied by growth inhibition in cHL cells in vitro. 5 Activation of signal transducer and activator of transcription (STAT) appears to play a role in cell growth and differentiation in certain hematopoietic cells, and shows a potential for preventing apoptosis during cell activation under certain conditions. 8, 9 STAT3, specifically, has been found to be constitutively activated in some solid tumors as well as in certain hematopoietic malignancies (for detailed reviews, see also Bromberg 10 and Yu and Jove 11 ). STATs are latent cytoplasmic transcription factors transducing signals from the cell membrane to the nucleus. Upon tyrosine phosphorylation, STAT proteins usually become activated in response to growth factors and cytokines. STATs usually get phosphorylated by protein tyrosine kinases (PTKs) of the Jak family and translocate to the nucleus, where they bind to defined DNA elements within the promoter region of target genes and induce transcription of genes involved in proliferation and apoptosis regulation. 12 Pharmacologically effective agents that can block STAT3 activation have a potential as therapeutical agents for the treatment of cHL. This may also be important with respect to the resistance to conventional therapies and relapse due to intense antiapoptotic pathways activated in cHL cells. [13] [14] [15] Tyrphostins represent a novel class of PTK inhibitors. Some of these compounds usually compete with the kinase substrate, are highly selective and show antitumor activity in vitro and in vivo. 16 Tyrphostin AG490 has been widely used and shown to prevent STAT3 signaling. [17] [18] [19] AG490 pretreatment also leads to sensitization for CD95-mediated apoptosis, also affecting STAT3-mediated Bcl-x L expression. [20] [21] [22] [23] A comparative analysis of different PTK inhibitors has shown that, in addition to AG490, AG17 may serve as an effective inhibitor of cHL cell proliferation (own unpublished observation).
5 AG17, known to inhibit PDGF-receptor signaling, is effective in inhibition of TNF signaling or affecting the cell cycle. [24] [25] [26] We hypothesize that STAT3 signaling is important in cHL and AG17 represents a potential drug prototype to block constitutively activated STAT3 in cHL cells, thereby rendering these lymphoma cells sensitive to apoptosis. Thus, in this study, we investigated the effect of AG17 and the resultant inhibition of constitutively active STAT3 on cHL cell proliferation and apoptotic sensitivity.
We provide evidence for a central role of STAT3 in cHL transducing signals downstream of PTKs that regulate growth of cHL cells, where inhibitors of PTKs that block STAT3 signaling represent potential novel therapeutics for cHL.
Materials and methods

Cell lines
The cHL cell lines L428, L540, L591, L1236, HDLM2, and KMH2, or T-cell lymphoma cells Jurkat were used as described previously. 5, 27 L428 cells stably expressing pSUPERneo, pSUPERneoGFPsi, or pSUPERneoSTAT3si were maintained in cell culture medium supplemented with 1 mg/ml Geneticin (G418) (Invitrogen/Gibco, Karlsruhe, Germany). During the proliferation assay, the cells were analyzed by counting them using the CASY s cell counter (Schärfe System, Reutlingen, Germany).
Vector construction and cell transfection
The expression vector pSUPERneo was obtained from OligoEngine (Seattle, WA, USA). The vector pSUPERneoSTAT3si was generated by cloning a EcoRI/HindIII Fragment from the vector pSUPERSTAT3si containing the STAT3-specific RNAi sequence GATCCCCTTCAGACCCGTCAACAAATTCAAGAGATTTGTTG ACGGGTCTGAAGTTTTT.
Oligonucleotide sequences
The oligonucleotide GATCCCCGGCTACGTCCAGGAGCGCA TTCAAGAGATGCGCTCCTGGACGTAGCCTTTT for constructing pSUPERneoGFPsi was kindly provided by O Witt (Gö ttingen) and cloned into the BglII/HindIII site of pSUPERneo. All vectors were sequenced using M13rev-primer and Big-Dye sequencing reagents according to the manufacturer (Applied Biosystems (ABI), Weiterstadt, Germany). Oligonucleotides for cloning and sequencing were obtained from IBA (Gö ttingen, Germany). Transfection of L428 cells was performed as described recently. 28, 29 Plasmids were introduced into L1236 cells by nucleofection as recommended by the manufacturer (Amaxa, Kö ln, Germany) with program A23 using buffer R.
Inhibitors of protein kinases
AG490 (B42) (a-cyano-(3,4-dihydroxy)-N-benzylcinnamide), AG17 (A9) (a-cyano-(3,5-di-t-butyl-4-hydroxy)cinnamonitrile), AG30 (a-cyano-(3,4-dihydroxy)cinnamic acid), AG18 (A23) (acyano-(3,4-dihydroxy)cinnamonitrile), staurosporine (STS), and SB202190 (4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole) were purchased from Calbiochem (Schwalbach/Darmstadt, Germany). Stock solutions were prepared in DMSO and diluted to the appropriate concentrations in culture medium. An equivalent dilution of DMSO was used as control.
Immunostaining of proteins
For Western blot analysis, cells were harvested as described recently. 5 Proteins were separated on a discontinuous SDS-PAGE before electroblotting onto nitrocellulose filters (Hybond C extra, Amersham, Freiburg, Germany). The blots were incubated with mouse monoclonal antibody directed against STAT6 (BD (Becton Dickinson), San Jose, CA, USA) or phospho-STAT6-Tyr 641 , rabbit polyclonal antibody directed against STAT3, phospho-STAT3-Tyr 705 , p38, phospho-p38 (Cell Signaling Technology, Schwalbach, Germany), or poly(ADP-ribose)-polymerase (PARP; Roche Molecular Biochemicals, Mannheim, Germany) at a dilution 1 : 1000 over night at 41C, followed by an incubation with a peroxidase-coupled second antibody (goat a-rabbit (New England Biolabs, Schwalbach, Germany) or goat a-mouse (Santa-Cruz Biotechnology, Santa Cruz, CA, USA at 1 : 2000). Blots were developed using the ECL system (Amersham). After the phospho-specific staining, the membranes were reprobed with the respective non-phospho-specific antibody. P38/SAPK2 control cell extracts treated with or without anisomycin were obtained from Cell Signaling Technology.
Gel retardation assays
Nuclear extracts for STAT3 and NF-kB detection were prepared as described previously. 5 Oligonucleotides used were purchased from Eurogentec (Serain, Belgium). Supershift antibodies against NF-kB/p65 were purchased from Santa Cruz Biotechnology. Supershifts were performed by incubating the nuclear extracts with the respective antibody for 45 min at room temperature before adding the radiolabeled oligonucleotide to the binding reaction mixture.
Cell cycle analysis and apoptotic assays
To quantify the induction of cell cycle arrest and apoptosis by tyrphostins, cells were plated with 5 Â 10 5 cells/ml. Inhibitors or corresponding amounts of DMSO were added to the cells and harvested as indicated in figure legends. For cell cycle analysis and detection of the leakage of fragmented DNA from apoptotic nuclei, nuclei were prepared using a hypotonic propidium iodide (PI) lysis buffer (0.1% sodium citrate, 0.1% Triton X-100, 50 mg/ml PI). 27 Nuclei to the left of the 2 N peak containing hypodiploid DNA were considered as apoptotic. In addition, phosphatidylserine externalization of apoptotic cells was measured by annexin-V staining (BD), followed by flow cytometric analysis. The increase in the number of annexin-Vpositive cells after tyrphostin treatment was analyzed in the presence or absence of 100 ng/ml a-CD95 antibody CH-11 (Immunotech, France) compared to an isotype control or after STS incubation at 1 mM and harvested as indicated in figure legends. All flow cytometric analyses were performed on a FACSscan (BD) using CellQuest analysis software.
For fluorimetric detection of caspase-3-like (DEVDase) activity, cytosolic cell extracts were prepared by lysing cells in a buffer containing 0.5% NP-40, 20 mM HEPES, pH 7.4, 84 mM KCl, 10 mM MgCl 2 , 0.2 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 5 mg/ml aprotinin, 1 mg/ml leupeptin, 1 mg/ml pepstatin and 1 mM PMSF. Caspase activities were determined by incubation of cell lysates with 50 mM of the fluorogenic substrate DEVD-AMC (Nacetyl-Asp-Glu-Val-Asp-aminomethylcoumarin, Bachem, Heidelberg, Germany) in 200 ml buffer containing 50 mM HEPES, pH 7.3, 100 mM NaCl, 10% sucrose, 0.1% CHAPS and 10 mM DTT. The release of aminomethylcoumarin was measured by fluorometry using an excitation wavelength of 360 nm and an emission wavelength of 475 nm. 27 
Results
Tyrphostin AG17 selectively inhibits cell proliferation of cHL cell lines accompanied by cell cycle arrest
Recently, we compared a number of PTK inhibitors and their capacity to affect proliferation and survival of cHL cells. Among them AG17 was found to inhibit proliferation and cell survival STAT3 is essential for Hodgkin lymphoma cells U Holtick et al of cHL cells at concentrations 10 times less compared to AG490. AG18 or AG30 was ineffective, influencing cHL cell proliferation at concentration of 100 mM (unpublished own observation). For L428 and L1236 cHL cells, the IC 50 values were calculated (Figure 1a,b) . In L428 cells, AG17 displayed a half-maximal inhibitory concentration (IC 50 ) of 41 nM. In L1236 cells IC 50 was 122 nM for AG17. AG490 displayed a halfmaximal inhibitory concentration in L428 of 38 mM and in L1236 of 1 mM.
Next, we examined whether the decrease in cell proliferation by AG17 was accompanied by cell cycle arrest. AG17 induces arrest at the G1 phase of the cell cycle in other cell systems. 24, 26 AG17 or AG490 was added to the cells for 24 h and analyzed for the induction of hypodiploid apoptotic nuclei and DNA content. Both tyrphostins caused the accumulation of L428 cells in G1 phase (Figure 1b) . In all 61 and 64% of cells were in G1 phase after AG17 or AG490 treatment, respectively, while less than 50% of control cells (DMSO treated) are in G1 phase. Nearly the same amount of cells in G1 phase were found after treatment with AG18 (49%), AG30 (48%), or SB202180 (45%). In L1236 cells 45 and 51% of cells are in G1 after AG17 or AG490 treatment, respectively ( Figure 1d ) compared to 35% when treated with DMSO, AG18, AG30 or SB202180. The apoptotic nuclei present in DMSO-treated L1236 cells were due to the permanent presence of cell debris. 15 
Different degree of induction of apoptosis in cHL cells after treatment with AG17
To evaluate whether induction of apoptosis could be mediated by tyrphostins, cHL cells were analyzed for increased numbers of annexin-V-positive cells. Cells were incubated for 24 h with AG17, AG490, or DMSO, stained with PI together with annexin-V-FITC. In Figure 2a the results of flow cytometry for L428, L540, L591, L1236, and KMH2 cells are summarized, showing enhanced numbers of annexin-V-positive cells after AG17 treatment, when compared to DMSO-treated cells (Figure 2a) . Treatment of cHL cells with AG30 showed no enhancement of apoptosis, when compared to DMSO-treated cells (data not shown), whereas AG490 treatment affected numbers of annexin-V-positive cells, indicating induction of apoptosis (Figure 2a) . The degree of apoptosis varied between the different cHL cell lines analyzed. Furthermore, it was obvious that tyrphostin-treated cells characterized by enhanced apoptosis (annexin-V staining) also displayed a lack of membrane integrity (PI staining) that might be attributed to the occurrence of post-apoptotic necrosis. While AG17 in the case of L540 or L591 mediated an increase in annexin-V-positive cells, in L428 and KMH2 cells only marginal enhancement in the number of annexin-V-positive cells was found within 24 h (Figure 2a ), but in L428 cells was enhanced within 72 h (data not shown). Increased number of annexin-V-positive cells was detected in L1236 cells after tyrphostin treatment for 24 h, even on the background of high amounts of spontaneously occuring cell debris also stained for annexin-V. 15 To further characterize the capacity of AG17 to induce apoptosis, L540, L591, and L1236 cells were treated with DMSO, AG17, or AG490 for 6 and 24 h and compared with the effects of STS, a potent apoptotic stimulus. Activation of caspases was monitored by the proteolytic cleavage of the caspase substrate PARP and the caspase-3-like catalytic activity in a fluorogenic substrate assay (Figure 2b and c) . 27 STS treatment was associated with a strong proteolytic degradation of PARP in L540 and L591 cells. In agreement with published data for L1236 cells only a slight cleavage of PARP was (Figure 2b ). 30 Incubation of L540, L591 and L1236 cells with AG17 led to cleavage of PARP already within 6 h and was enhanced after 24 h of treatment. After 6 h PARP cleavage was less pronounced in L591 and L1236 cells than in L540 cells. AG490 had a stronger effect on PARP cleavage in all three cell lines than AG17, but was still less effective than STS treatment. PARP cleavage and increased annexin-V positivity went along with high DEVDase activity in L540 cells. Lower DEVDase activity was observed in L591 and L1236 cells compared to L540 cells after tyrphostin treatment. These observations are in agreement with the finding that the proteolytic degradation of PARP in both cell lines is less distinct compared to L540 cells, but did not completely coincide with the increase in the number of annexin-V-positive cells ( Figure 2) .
As tyrphostin incubation of L428 failed to enhance the number of annexin-V-positive cells after 24 h substantially, we analyzed whether other classical apoptosis pathways are affected by PTK inhibitors after longer incubation times. L428 cells were treated with DMSO, AG17, AG490 for up to 72 h or STS for 24 h and analyzed for changes in the proteolytic cleavage of caspase-3 or -8 and PARP. 27 STS treatment was associated with a slight cleavage of PARP in these cells comparable to published data (data not shown). 30 Incubation of L428 cells with AG17 did not lead to activation of caspases or cleavage of PARP even after 72 h, whereas AG490 was able to mediate a marginal activation of caspase-8 and PARP after 72 h (data not shown). Analysis of caspase 3 and 8 processing by immunoblot showed that only in L540 cells a slight activation of caspase 8 is detectable, whereas caspase 3 was activated in L540 and L591 cells in a comparable way as PARP cleavage (data not shown). 
STAT3 is essential for Hodgkin lymphoma cells U Holtick et al
Tyrphostin AG17-induced inhibition of cell proliferation of cHL cell lines is accompanied by decreased constitutive activation of STAT3. Simultaneously to the proliferation assay, cell cycle analysis, and apoptosis assay, we tested tyrosine phosphorylation of STAT3 (Figure 3a) and STAT3 DNA-binding activity in L428, L1236, and L540 cells (Figure 3b ). We found that AG17 treated cells were characterized by complete loss of phosphorylated STAT3, accompanied by a slight reduction in STAT3, protein expression when analyzed after 48 h (Figure 3a,  c and d) . Comparable results were obtained using AG17 at 5 mM (see also Figure 6 ). Already 4-6 h after addition of tyrphostins the amount of phosphorylated STAT3 was decreased (Figure 3c and d). AG490 treatment also went along with reduced STAT3 phosphorylation, but was less pronounced compared to AG17. Comparable results were obtained using AG490 at 75 mM (see also Figure 6 ). AG18 treatment, which could not inhibit proliferation, showed no effect on STAT3 phosphorylation or STAT3 protein level (Figure 3a) . The same was found for AG30-treated cells (data not shown). Gel retardation assays demonstrated that nuclear extracts from untreated cHL cells formed specific protein-DNA complexes as shown previously. 5 Treatment with AG17 led to reduced DNA binding of STAT3 after 24 h as known from AG490 (Figure 3b) . 5 AG18 did not alter DNA binding of STAT3 in the analyzed cell lines (Figure 3b) .
Next we tested the influence of tyrphostins on NF-kB and p38/ SAPK2 signaling. L428 and L540 cells were analyzed for DNA binding of NF-kB (Figure 4a) . No decrease in DNA binding of NF-kB was observed in L428 and L540 cells 6 h after treatment with AG18, AG490, and AG17 at a concentration of up to 100 mM, where STAT3 tyrosine phosphorylation already decreases (Figure 3c NF-kB and p38/SAPK2 signaling is not inhibited through treatment with the tyrphostins AG17, AG18 and AG490 in cHL cells. (a) DNA-binding of NF-kB is not inhibited by AG17, AG18, or AG490 in L428 and L540 cells within 24 h Oligonucleotide sequence used: AGCTTCAGAGGGGACTTTCCGAGAGG. (b, c) Western blot analysis of phosphorylated or unphosphorylated p38/SAPK2. Phosphorylation and expression of p38 is not inhibited by AG17 or AG490 after incubation of L428, L540 and L1236 cells for 24 h. Lysates from untreated or anisomycin-treated C-6 glioma cells were used as p38/ SAPK2 reference lysate. AG17 (10 mM), AG18 (100 mM), and AG490 (100 mM) were used at indicated concentrations.
STAT3 is essential for Hodgkin lymphoma cells
U Holtick et al of p38/SAPK2 was not inhibited by tyrphostin treatment in the analyzed cell lines, but a slightly enhanced phosphorylation of p38 was observed in L1236 cells (Figure 4b and c) .
Owing to their different cellular origin, their clinical stage and subgroup of cHL, cHL cell lines are heterogeneous in their phenotype. They also differ in their degree of constitutively activated STAT3, where the T-cell-derived cells L540 and HDLM2 are characterized by highest levels, as shown recently. 5 The differences in STAT3 activation do not reflect the capacity of AG17 or AG490 to induce apoptosis. The T-cell-derived L540 cells show high degrees in tyrphostin-mediated apoptosis and high levels of permanent STAT3 activation, compared to the Bcell-derived L428 or L1236 cells. The other T-cell-derived cell line HDLM2 is also characterized by high constitutively activated STAT3, but displays no apoptosis resistance at all. Such differences already have been described by Hinz and colleagues comparing NF-kB inactivated HDLM2 T-cell-derived and L428 B-cell-derived cHL cells. 31 
Tyrphostin treatment of Hodgkin lymphoma cell lines sensitizes cHL cells for CD95-and for staurosporineinduced apoptosis
Previously, it was demonstrated that B-cell-derived cHL cells are resistant to CD95-mediated apoptosis; however, inhibition of the STAT3 signaling by AG490 sensitizes U266 myeloma cells for CD95-triggered apoptosis. 14, 15, 22 In order to test the capacity of AG17 to sensitize cHL cells to CD95-mediated programmed cell death, L428 cells were stimulated with agonistic a-CD95 antibodies in combination with tyrphostins. Jurkat cells were used as an internal control for CD95-mediated apoptosis and were treated as described previously (data not shown). 15, 27 To estimate apoptosis sensitization, L428 cells were treated with AG490, AG30, AG17, or DMSO for 48 h and coincubated for additional 24 h with a-CD95 antibody or isotype control, demonstrating a strong susceptibility to CD95-mediated apoptosis ( Figure 5 ). The coincubation of isotype control antibody with DMSO-or AG30-treated cells with a-CD95 antibody showed no effects ( Figure 5 ). AG490-pretreated L428 cells showed enhanced CD95-mediated apoptosis, but were not as effectively sensitized as by AG17 ( Figure 5 ). Comparable effects were observed for KMH2 (data not shown). In L540 or L591 cells, tyrphostinmediated apoptosis was further enhanced by CD95 crosslinking within 24 h of coincubation (data not shown). The cell line HDLM2 was already CD95 sensitive. L1236 cells are characterized by a CD95 deletion, leading to the expression of a dominant-negative receptor, thus a CD95 experiment was omitted. 14, 15, 32 While demonstrating that tyrphostin pretreatment confers sensitivity to CD95-mediated apoptosis in cHL cells, we next wanted to analyze the capacity of AG17 to overcome STS resistance. 30, 33 Figure 6a summarizes data demonstrating that incubation of cHL cells (L428, L540, L591, and KMH2) with AG17 or AG490 rendered these cells sensitive for STS-mediated apoptosis. The cHL cell lines L540, L591, and L1236 respond to some extent to STS treatment after 24 h, whereas L428 and KMH2 cells were less sensitive as already described (Figure 6a) . 30 In L540, L591, and L1236 cells, a further increase in the number of annexin-Vpositive cells was observed, whereas in KMH2 the coincubation of the tyrphostin with STS led to rapid apoptosis followed by complete cell death (Figure 6a) . In L428 cells an enhancement in annexin-V staining was observed in AG17-treated cells stronger than by AG490, however to an extent less pronounced Figure 5 Pretreatment of L428 cHL cells with AG17 or AG490 sensitizes these cells for CD95-mediated apoptosis. L428 cells were preincubated with DMSO, AG17 (5 mM) , AG30 (75 mM), AG490 (75 mM) for 48 h. In all, 100 ng/ml of isotype-matched control antibody or CD95-activating antibody was added to the cells for additional 24 h. Apoptosis was then analyzed by annexin-V staining, as described in the legend to The analysis of STAT3 phosphorylation in L428 and L1236 cHL cells, which are characterized by low tyrphostin-associated apoptosis, revealed a complete inhibition of constitutively activated STAT3 within 4 h after coincubating the cells with STS and AG17 or AG490 (Figure 6b and c) . Within 24 h of coincubation, not only the constitutive activation of STAT3 was completely abrogated but also STAT3 protein expression was decreased, because of cell death (data not shown). It has been shown that constitutively activated STAT6 may play a role in cHL, the tyrosine phosphorylation was also analyzed in this context. 7 Decreased STAT6 phosphorylation was observed in tyrphostin-and STS-treated cells after 4 h, but the effect on STAT3 phosphorylation was stronger (Figure 6b and c) .
Our present findings suggest that inhibition of constitutively activated STAT3 by tyrphostins AG17 or AG490 could be responsible for inhibition of cell proliferation, but not neccessarily for apoptosis resistance.
Since STAT3 activation is attributed to one or more PTKs, it would be interesting to identify the PTKs involved in activation of STAT3 in cHL cells. Candidate PTKs are the members of the Jak-or src-family, but also 'SOCS3-resistant oncogenic kinases', as suggested recently, have to be taken into account. 12, 34 Furthermore, those PTKs targeted by AG17 or AG490 but not STS have to be identified in addition to STAT3-activating PTKs, because it has to be considered that the analyzed PTK inhibitors may well inhibit not only STAT3.
Generation of HL cell lines with artificially blocked STAT3 expression
To answer the question if STAT3 is involved in vital functions of cHL cells and to further understand the tyrphostin-mediated inhibition of constitutively activated STAT3, the method of RNA interference was used to downregulate STAT3 expression in cHL cells.
L428 and L1236 cells were transfected with a STAT3 siRNAexpressing vector (pSUPERneoSTAT3si), empty vector (pSUPERneo), or pEGFP and pEGFP/pSUPERneoGFPsi as additional controls. Transfected cells were enriched as described previously. 28 Cells were analyzed for STAT3 levels up to 72 h after enrichment (data not shown).
The transfection of L1236 cells with pSUPERneoSTAT3si was associated with a complete absence of G418-resistant cells compared to pSUPERneo or pSUPERneoGFPsi in three independent transfection experiments. This suggests that STAT3 is Membranes were stained first with phospho-STAT3-specific antibodies, afterwards stained for STAT3 protein, followed by staining with phospho-STAT6-specific antibodies and for STAT6 protein.
STAT3 is essential for Hodgkin lymphoma cells
U Holtick et al directly involved in cellular proliferation and survival of L1236 cells. Comparable effects were described recently analyzing the NF-kB pathway in cHL cells. 35 Transfection of L428 cells with pSUPERneoSTAT3si was performed, but did not reveal comparable results as obtained for L1236 cells. After G418 selection we investigated a representative number of L428 cells containing pSUPERneoSTAT3si. Among the outgrowing G418-resistant cells, a number of clones were established and characterized by Western Blot analysis. These L428 clones showed reduced expression of STAT3 protein (Figure 7a ).
Constitutively activated STAT3 is required for proliferation of cHL tumor cells We also analyzed the expression of CD40 and CD54 that are regulated through NF-kB in cHL cells. 36 Both proteins showed no differences in the expression level, assuming that NF-kB activation is not affected by STAT3 inhibition (data not shown). In summary, the important finding of this study is that STAT3 is essential for cHL cell proliferation, as shown by knockdown of this transcription factor. Another important finding is that the tyrphostin AG17 is a potent inhibitor of constitutively activated STAT3 in cHL cells. Reduced STAT3 phosphorylation was accompanied with cell cycle arrest, reduced cellular proliferation and enhanced apoptosis. As PTK inhibitors may well inhibit not only STAT3, the corresponding specific knockdown of STAT3 was performed, strongly supporting the role of STAT3 for proliferation of cHL cells L1236 and L428.
A characteristic feature of cHL are multiple deregulated signaling pathways. 37 NF-kB signaling in cooperation with the Notch pathway or c-jun/Jun-B as well as the MEK/ERK pathway were described to be aberrantly deregulated in cHL cells. 7, [38] [39] [40] Our experiments support the hypothesis that constitutively activated STAT3 and STAT6 are involved in cHL pathophysiology. 5, 7 Both STAT3 knockdown as shown in the present study and inhibition of NF-kB signaling by dominant-suppressive IkBa affect HRS cell proliferation. 35 We cannot discriminate the relative contribution of NF-kB, AP1, MEK/ERK, or STAT molecules in HRS cell proliferation and target gene regulation. Several target genes have been described, where STAT3 and NFkB share binding sites or are characterized by close proximity within corresponding promoter regions. 41 Another possibility is a direct protein-protein interaction of STATs with NF-kB or other transcription factors. 42, 43 It raises also the possibility that antiapoptotic genes are regulated in cHL cells in a redundant or cooperative manner by several STAT factors and NF-kB. 5, 7, 31 In conclusion, our data highlight the biological importance of STAT3 in promoting cell proliferation in cHL. Our findings demonstrate that the tyrphostins AG17 and AG490 are potent inhibitors of the STAT3 pathway and a potent class of compounds capable of reversing apoptosis resistance in cHL. In view of the importance of the STAT3 pathway in the pathogenesis of cHL, this pathway may serve as a potential target for therapeutic intervention. 
